Uh-oh, he’s back: Fauci is once again spouting bad COVID advice

Uh-oh, he’s back: Fauci is once again spouting bad COVID advice
Photo Credit: Kevin Dietsch-Pool/Getty Images

Controversial ex-COVID czar Anthony Fauci reemerged this week to urge that, because of rising infection rates, we consider a return to comprehensive masking protocols. That’s bad health-care policy, because it doesn’t follow the science. No wonder nobody’s listening to Dr. Fauci.

Let’s face it: public-health messaging and open, honest debate haven’t been the Good Doctor’s strong suits. He’s the wrong man, at the wrong time, with the wrong advice. But the big problem is a misunderstanding of what’s actually going on.

Following large-scale vaccination efforts and the introduction of the various Omicron variants, states and municipalities with more robust masking regulations have not fared better than those with more targeted strategies for reducing the prevalence of serious disease. Even with today’s significantly more infectious COVID-19 strains, the number of serious viral manifestations remain very low — and, in the majority, most of them impact unvaccinated and high-risk individuals.

So whether or not masking was good at preventing the spread of COVID before vaccines became available, it certainly is not so today. And it’s doubly foolish to use infection rates to trigger a return to widespread masking. Prior to mass vaccination, such rates were an excellent predictor of both hospitalization and death rates; today, they’re still an important data point — but they’re no longer a key indicator of public-health danger.
 
Sign Up for Our Email Newsletter

RECENT NEWS

Unmasking the Real Cost Drivers in U.S. Healthcare: A Critical Examination of Hospital Pricing and Policy Reform

Unmasking the Real Cost Drivers in U.S. Healthcare: A Critical Examination of Hospital Pricing and Policy Reform

From 2000 to 2020, the U.S. saw more than 1,600 hospital mergers. These consolidations have led to decreased competition,...  Read more

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

Differing philosophies within and outside of government could doom the hub...  Read more

Countries Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation - What Can the US Do to Change That?
  • RCJ
  • 05/09/2025 12:00 AM

Countries Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation - What Can the US Do to Change That?

The principal reason for the disparity in biopharmaceutical pricing is that governments in other developed countries use ...  Read more

DRUGWONKS BLOG